DelveInsight's analysis estimates that the postherpetic neuralgia market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A..
Reviewing Novavax (NASDAQ:NVAX) & BioCryst Pharmaceuticals (NASDAQ:BCRX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership. Volatility & Risk BioCryst Pharmaceuticals has a beta […]
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.